Solvay advances bio-based innovation, invests in DMC Biotechnologies
Solvay Ventures, the venture capital fund of Solvay, has invested in DMC Biotechnologies, a U.S.-based biotechnology company. DMC, which stands for Dynamic Metabolic Control, delivers robust and predictably scalable biocatalysts through microbial fermentation. This results in cost-competitive bio-based chemicals produced for animal feed, human nutrition, sustainable cleaning and pharmaceutical applications.
DMC represents Solvay Venture's first portfolio company in biotechnology. Its core technology addresses a key challenge for biotech companies, considered to be the next wave of a biotechnology paradigm, as it decouples cell growth and production while optimizing metabolic pathways in each phase. This optimization results in unprecedented yields and predictability for scale-up.